Mesoblast Ltd
Rexlemestrocel-L
Chronic low back pain
Countdown
633days
FDA decision · ~ Mar 31, 2028 estimated
What's at stake
The FDA's approval decision on Rexlemestrocel-L for Chronic low back pain is due ~ Mar 31, 2028. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“Expect to file BLA for full approval next quarter”